Further studies have implicated NUBPL dysregulation in gastric cancer and bladder cancer, with high NUBPL expression predicting poor prognosis and reduced responsiveness to immune checkpoint inhibitors [22]. The gene discussed is NUBPL; the disease is urinary bladder cancer.